You Position: Home > Paper

Evaluation of efficacy and safety of Gansulin 50R versus Novolin 50R in treatment of diabetic patients: A multicenter, randomized, opened and controlled clinical trial

( views:686, downloads:343 )
Author:
No author available
Journal Title:
CHINESE JOURNAL OF DIABETES
Issue:
10
DOI:
10.3321/j.issn:1006-6187.2008.10.018
Key Word:
糖尿病;甘舒霖50R;有效性;安全性;Diabetes mellitus

Abstract: Objective A multicenter, randomized, opened and controlled clinical trial was performed to compare the efficacy and safety of Gansulin 50R and Novolin 50R in type 1 and type 2 diabetes. Methods 480 cases were randomized into two groups(3∶1)treated with Gansulin 50R versus Novolin 50R for 12 weeks respectively. Results Compared with pretreatment,at the end of 12 weeks’treatment,the decreased values of HbA1c(0.91% vs 0.94%), FPG(1.56 mmol/L vs 1.61 mmol/L) and 2hPG(3.35 mmol/L vs 3.53 mmol/L) were all proved significantly in both Gansulin 50R group and Novolin 50R group(all P<0.05). And the changes of HbA1c from baseline to endpoint were similar between the two treatment groups (P>0.05). Overall, all adverse events,including hypoglycemic events and the incidence of nocturnal hypoglycemia were similar between both groups(P>0.05). Conclusions Gansulin 50R and Novolin 50R have similar efficacy and safty profiles in the treatment of diabetic patients

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn